PDLIM2 and ovarian carcinoma: In ovarian cancer (OV), PDLIM2 is epigenetically suppressed, and PDLIM2 inhibition promotes OV growth in vivo and in vitro via NOS2-derived nitric oxide signaling, leading to M2-type macrophage recruitment [115].